Shiva Malek - Director, Principal Scientist, Discovery Oncology

Shiva Malek

Director, Principal Scientist, Discovery Oncology

Postdoc Mentor
"I am inspired by patients whose lives we impact and Genentech scientists whose relentless approach to studying cancer biology has resulted in transformative therapies."
11
Years at Genentech
30
Publications
7
Awards & Honors

I joined Genentech in 2006 for the opportunity to conduct cutting edge basic science research and build the small molecule drug discovery division at Genentech. I am currently Associate Director in the Department of Discovery Oncology. My department is responsible for identification and validation of targets for multiple oncology indications. We focus on studying tumor vulnerabilities through in-depth investigation of mechanisms driving mutated cancer pathways. Through understanding how mutational dysregulation of these pathways drives disease, we aim to uncover novel approaches for therapeutic intervention.

We use a variety of approaches to validate targets including target-focused approaches such as genetic knockdowns or small molecule inhibitors as well as functional genomics screening approaches. We are interested in tackling the most difficult of problems including discovering novel strategies to target RAS mutant tumors. Our department collaborates closely with many other groups at Genentech including the Bioinformatics, Translational Oncology, Proteomics, Small Molecule Drug Discovery and Antibody Engineering groups.

Postdoctoral Mentor

Post-doctoral fellows at Genentech have the unique opportunity to conduct basic science research and leverage cutting edge technology platforms that have been developed in-house. Through multi-disciplinary collaborations (such as with Bioinformatics, Proteomics, Structural Biology, and Translational Oncology), many post-doctoral fellows are able to take on the most difficult of scientific problems and make high-impact, long-lasting contributions to their field. Mentoring post-doctoral fellows is one of the most enriching experiences I have had at Genentech.

Featured Publication

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Nature 2010 Feb 3. [Epub ahead of print]

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling.

Cancer Cell. 2014 Sep 8;26(3):402-13. doi: 10.1016/j.ccr.2014.07.007. Epub 2014 Aug 21.

Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, Bravo BJ, Giannetti AM, Peck A, Masselot A, Morales T, Smith D, Brandhuber BJ, Hymowitz SG, Malek S.